TickerFacts.

A business in context

ARTV research notebook

Read the disclosures. Follow the relationships. Keep the dates in view.

Research JSON

Filing timeline

Download filings CSV

SEC submissions · retrieved 2026-10-23 · 8022 issuers; up to 32 recent company reports and 8 ownership-change filings per issuer

  1. 4 · Ownership change

    Report date 2026-10-06 · 0001193125-26-416953

  2. 4 · Ownership change

    Report date 2026-10-05 · 0001193125-26-415531

  3. 4 · Ownership change

    Report date 2026-10-05 · 0001193125-26-415529

  4. 4 · Ownership change

    Report date 2026-10-05 · 0001193125-26-415528

  5. 4 · Ownership change

    Report date 2026-10-05 · 0001193125-26-415527

  6. 4 · Ownership change

    Report date 2026-09-15 · 0001193125-26-392025

  7. 4 · Ownership change

    Report date 2026-09-10 · 0001231919-26-001173

  8. 4 · Ownership change

    Report date 2026-09-10 · 0001193125-26-391012

  9. 8-K · Current report

    Report date 2026-09-08 · 0001193125-26-389308 · Items 5.02,5.07,9.01

  10. 10-Q · Quarterly report

    Report date 2026-06-30 · 0001193125-26-338029

  11. 8-K · Current report

    Report date 2026-08-06 · 0001193125-26-337986 · Items 2.02,9.01

  12. DEF 14A · Proxy statement

    Report date 2026-09-08 · 0001193125-26-330563

  13. 8-K · Current report

    Report date 2026-07-22 · 0001193125-26-312560 · Items 8.01

  14. 8-K · Current report

    Report date 2026-05-18 · 0001193125-26-229714 · Items 5.02

  15. 8-K · Current report

    Report date 2026-05-08 · 0001193125-26-214711 · Items 8.01,9.01

  16. 10-Q · Quarterly report

    Report date 2026-03-31 · 0001193125-26-213242

  17. 8-K · Current report

    Report date 2026-05-08 · 0001193125-26-213239 · Items 2.02,7.01,8.01,9.01

  18. 10-K/A · Annual report

    Report date 2025-12-31 · 0001193125-26-197115

  19. 10-K · Annual report

    Report date 2025-12-31 · 0001193125-26-100135

  20. 8-K · Current report

    Report date 2026-03-10 · 0001193125-26-100131 · Items 2.02,9.01

  21. 8-K · Current report

    Report date 2026-02-18 · 0001193125-26-067509 · Items 5.02

  22. 8-K · Current report

    Report date 2026-02-18 · 0001193125-26-059716 · Items 5.02

  23. 8-K · Current report

    Report date 2025-12-10 · 0001193125-25-317784 · Items 5.02

  24. 8-K · Current report

    Report date 2025-11-12 · 0001193125-25-275902 · Items 7.01,8.01,9.01

  25. 10-Q · Quarterly report

    Report date 2025-09-30 · 0001193125-25-275872

  26. 8-K · Current report

    Report date 2025-11-12 · 0001193125-25-275867 · Items 2.02,9.01

  27. 10-Q · Quarterly report

    Report date 2025-06-30 · 0000950170-25-104045

  28. 8-K · Current report

    Report date 2025-08-06 · 0000950170-25-104028 · Items 2.02,9.01

  29. 8-K · Current report

    Report date 2025-06-24 · 0000950170-25-089942 · Items 5.02,5.07,9.01

  30. 10-Q · Quarterly report

    Report date 2025-03-31 · 0000950170-25-066421

  31. 8-K · Current report

    Report date 2025-05-08 · 0000950170-25-066416 · Items 2.02,9.01

  32. DEF 14A · Proxy statement

    Report date 2025-06-24 · 0001193125-25-101364

  33. 10-K · Annual report

    Report date 2024-12-31 · 0000950170-25-043837

  34. 8-K · Current report

    Report date 2025-03-24 · 0000950170-25-043828 · Items 2.02,9.01

  35. 8-K · Current report

    Report date 2025-01-28 · 0000950170-25-010481 · Items 5.02,9.01

  36. SC 13G/A · Ownership disclosure

    0000905148-24-003191

  37. 10-Q · Quarterly report

    Report date 2024-09-30 · 0000950170-24-125382

  38. 8-K · Current report

    Report date 2024-11-12 · 0000950170-24-125359 · Items 2.02,9.01

  39. 8-K · Current report

    Report date 2024-10-21 · 0001193125-24-241059 · Items 5.02,9.01

  40. SC 13D/A · Ownership disclosure

    0001104659-24-096378

Reported insider transactions

Download transactions CSV

SEC insider transactions · retrieved 2026-10-23 · 2026 Q3: filings in this completed quarter; not a live transaction feed

Purchases and sales include open-market or private transactions. Grants, exercises and tax withholding are shown separately. Amendments and joint reports can overlap; rows are not a net-buying score. Prices retain the filing's units; consult its footnotes.

Transaction rows by code · counts, not monetary totals
Purchase: 11 transaction rows11PSale: 7 transaction rows7SGrant / award: 26 transaction rows26AExercise / conversion: 4 transaction rows4MTax / exercise payment: 0 transaction rows0FGift: 0 transaction rows0G
P · PurchaseS · SaleA · Grant / awardM · Exercise / conversionF · Tax / exercise paymentG · Gift

48 matching transaction rows.

Transaction / filedReporting ownerTypeSecuritySharesReported price
2026-09-15
2026-09-15
Aslan FredA · Grant / award
Acquired
Common Stock110000.00.0
2026-09-15
2026-09-15
Aslan FredA · Grant / award
Acquired
Employee Stock Option (Right to Buy)
Derivative security
315000.00.0
2026-09-10
2026-09-14
Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund III, L.P.; RA Capital Nexus Fund, L.P.; Shah Rajeev M.A · Grant / award
Acquired
Director Stock Option (Right to Buy)
Derivative security
16250.00.0
2026-09-10
2026-09-14
Aslan FredA · Grant / award
Acquired
Common Stock45000.00.0
2026-09-10
2026-09-14
Aslan FredA · Grant / award
Acquired
Employee Stock Option (Right to Buy)
Derivative security
155000.00.0
2026-09-10
2026-09-14
Stoppel LauraA · Grant / award
Acquired
Director Stock Option (Right to Buy)
Derivative security
16250.00.0
2026-09-10
2026-09-14
Sorg Elaine K.A · Grant / award
Acquired
Director Stock Option (Right to Buy)
Derivative security
16250.00.0
2026-09-10
2026-09-14
HOUGEN ELIZABETH LA · Grant / award
Acquired
Director Stock Option (Right to Buy)
Derivative security
16250.00.0
2026-09-10
2026-09-14
DANIELS BRIANA · Grant / award
Acquired
Director Stock Option (Right to Buy)
Derivative security
16250.00.0
2026-09-10
2026-09-14
Baker Daniel G.A · Grant / award
Acquired
Director Stock Option (Right to Buy)
Derivative security
16250.00.0
2026-09-10
2026-09-14
MOORE ALISONA · Grant / award
Acquired
Director Stock Option (Right to Buy)
Derivative security
16250.00.0
2026-09-09
2026-09-11
Miralles Gines DiegoA · Grant / award
Acquired
Common Stock45000.00.0
2026-09-09
2026-09-11
Miralles Gines DiegoA · Grant / award
Acquired
Employee Stock Option (Right to Buy)
Derivative security
135000.00.0
2026-09-09
2026-09-11
Horan ChristopherA · Grant / award
Acquired
Common Stock40000.00.0
2026-09-09
2026-09-11
Horan ChristopherA · Grant / award
Acquired
Employee Stock Option (Right to Buy)
Derivative security
120000.00.0
2026-09-09
2026-09-11
Bush JenniferA · Grant / award
Acquired
Common Stock45000.00.0
2026-09-09
2026-09-11
Bush JenniferA · Grant / award
Acquired
Employee Stock Option (Right to Buy)
Derivative security
135000.00.0
2026-09-09
2026-09-11
Banerjee SubhashisA · Grant / award
Acquired
Common Stock30000.00.0
2026-09-09
2026-09-11
Banerjee SubhashisA · Grant / award
Acquired
Employee Stock Option (Right to Buy)
Derivative security
85000.00.0
2026-09-08
2026-09-08
Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund III, L.P.; RA Capital Nexus Fund, L.P.; Shah Rajeev M.A · Grant / award
Acquired
Director Stock Option (Right to Buy)
Derivative security
13750.00.0
2026-09-08
2026-09-09
Aslan FredS · Sale
Disposed
Common Stock23429.010.92
2026-09-08
2026-09-08
Stoppel LauraA · Grant / award
Acquired
Director Stock Option (Right to Buy)
Derivative security
13750.00.0
2026-09-08
2026-09-08
Sorg Elaine K.A · Grant / award
Acquired
Director Stock Option (Right to Buy)
Derivative security
13750.00.0
2026-09-08
2026-09-08
HOUGEN ELIZABETH LA · Grant / award
Acquired
Director Stock Option (Right to Buy)
Derivative security
13750.00.0
2026-09-08
2026-09-08
DANIELS BRIANA · Grant / award
Acquired
Director Stock Option (Right to Buy)
Derivative security
13750.00.0
2026-09-08
2026-09-08
Baker Daniel G.A · Grant / award
Acquired
Director Stock Option (Right to Buy)
Derivative security
13750.00.0
2026-09-08
2026-09-08
MOORE ALISONA · Grant / award
Acquired
Director Stock Option (Right to Buy)
Derivative security
13750.00.0
2026-09-03
2026-09-04
Horan ChristopherS · Sale
Disposed
Common Stock10366.011.16
2026-09-03
2026-09-04
Bush JenniferS · Sale
Disposed
Common Stock8391.011.16
2026-09-03
2026-09-04
Banerjee SubhashisS · Sale
Disposed
Common Stock1100.011.16
2026-09-03
2026-09-04
Aslan FredS · Sale
Disposed
Common Stock61888.011.16
2026-08-27
2026-08-31
Banerjee SubhashisM · Exercise / conversion
Acquired
Common Stock5306.01.92
2026-08-27
2026-08-31
Banerjee SubhashisS · Sale
Disposed
Common Stock8222.012.01
2026-08-27
2026-08-31
Banerjee SubhashisM · Exercise / conversion
Disposed
Employee Stock Option (Right to Buy)
Derivative security
5306.00.0
2026-08-18
2026-08-19
Banerjee SubhashisS · Sale
Disposed
Common Stock429.012.0
2026-08-18
2026-08-19
Banerjee SubhashisM · Exercise / conversion
Acquired
Common Stock429.01.92
2026-08-18
2026-08-19
Banerjee SubhashisM · Exercise / conversion
Disposed
Employee Stock Option (Right to Buy)
Derivative security
429.00.0
2026-07-31
2026-07-31
Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund III, L.P.; RA Capital Nexus Fund, L.P.; Shah Rajeev M.P · Purchase
Acquired
Common Stock24944.09.93
2026-07-29
2026-07-31
Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund III, L.P.; RA Capital Nexus Fund, L.P.; Shah Rajeev M.P · Purchase
Acquired
Common Stock20824.09.99
2026-07-24
2026-07-28
Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund III, L.P.; RA Capital Nexus Fund, L.P.; Shah Rajeev M.P · Purchase
Acquired
Common Stock41319.09.99
2026-07-23
2026-07-23
Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund III, L.P.; RA Capital Nexus Fund, L.P.; Shah Rajeev M.P · Purchase
Acquired
Common Stock59880.09.96
2026-07-22
2026-07-23
Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund III, L.P.; RA Capital Nexus Fund, L.P.; Shah Rajeev M.P · Purchase
Acquired
Common Stock84124.09.93
2026-07-21
2026-07-23
Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund III, L.P.; RA Capital Nexus Fund, L.P.; Shah Rajeev M.P · Purchase
Acquired
Common Stock120582.09.55
2026-07-17
2026-07-20
Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund III, L.P.; RA Capital Nexus Fund, L.P.; Shah Rajeev M.P · Purchase
Acquired
Common Stock7882.08.95
2026-07-16
2026-07-20
Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund III, L.P.; RA Capital Nexus Fund, L.P.; Shah Rajeev M.P · Purchase
Acquired
Common Stock152472.08.93
2026-07-13
2026-07-23 · Amendment
Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund III, L.P.; RA Capital Nexus Fund, L.P.; Shah Rajeev M.P · Purchase
Acquired
Common Stock6522.08.94
2026-07-13
2026-07-14
Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund III, L.P.; RA Capital Nexus Fund, L.P.; Shah Rajeev M.P · Purchase
Acquired
Common Stock6552.08.94
2026-07-10
2026-07-14
Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund III, L.P.; RA Capital Nexus Fund, L.P.; Shah Rajeev M.P · Purchase
Acquired
Common Stock15102.08.97

Identity & relationships

Wikidata structured data · retrieved 2026-10-23 · 1658 unambiguous CIK-linked entities; coverage is incomplete

These are sourced identity and relationship claims, with incomplete coverage. Headquarters locations do not describe sales, assets or operating exposure.

SEC issuer · 0001817241Artiva Biotherapeutics, Inc.

No parent relationship is available in this import; this is not proof of independence.

No verified LEI join available.

GLEIF legal entity reference data · retrieved 2026-10-23 · 1197 checked identities; 0 unavailable records

Search names and former names

    Revenue in constant purchasing power

    USD revenue expressed in 2026-09 consumer-price dollars. Each annual period uses a CPI-U average weighted by the days in its actual reporting interval. This is a purchasing-power comparison, not a company-specific price or volume measure.

    Year endedReported USD revenueCPI-adjusted USD revenue
    2024-12-31$251.0K$269.6K
    2023-12-31$33.49M$37.03M

    Bureau of Labor Statistics · retrieved 2026-10-23 · 9 selected series; gaps remain missing

    Explore the CPI history ↗